Retatrutide's triple receptor activity produces stronger GI side effects than semaglutide or tirzepatide during dose escalation. Slow titration — increasing dose every 4 weeks rather than every 2 weeks — substantially reduces nausea and vomiting rates in research protocols.
| Weeks | Dose | Frequency |
|---|---|---|
| 1–4 | 1 mg | Once weekly |
| 5–8 | 2 mg | Once weekly |
| 9–12 | 4 mg | Once weekly |
| 13–16 | 8 mg | Once weekly |
| 17+ | 12 mg | Once weekly (max studied dose) |
Administer injections in the evening to allow peak plasma concentration to coincide with sleep. Reduce meal size on injection day. If nausea persists beyond week 2 at a given dose, hold the dose for an additional 4 weeks before escalating.
Research-grade retatrutide (2 mg vials) with COA available at QSC Peptides.
This page is for educational and research purposes only. All products sold by QSC are labelled for research use only and are not intended for human consumption. Nothing on this page constitutes medical advice.